欢迎来到山东大学技术转移中心!今天是
您现在的位置是: 首页 > 科技管家 > 专家库 > 生物医药 > 正文
刘新泳
作者:TTC   来源:   浏览次数:
\

山东大学校聘二级岗教授,博士生导师,享受国务院政府特殊津贴;现任药学院副院长,药物化学研究所所长,教研室主任;山东省新药设计与创新药物研究重点实验室主任;山东省保健科技协会常务理事;国家SFDA保健食品审评专家、国家科学技术奖励评审专家、科技部国际合作重点项目评审专家;山东省药学会理事、副秘书长;国际杂志“E-Journal of Chemistry (IF0.58)”学术编辑(Academic Editor);国际著名期刊 “Current Medicinal Chemistry”(IF4.961)“Drug Discoveries & Therapeutics”“World Journal of Virology”“World Journal of Pharmacology”“World Journal of Clinical Infectious Diseases” “Virology Discovery”“Interactive Medicinal Chemistry” 编委;《中国药物化学杂志》、《中国医药工业杂志》、《山东大学学报(医学版)》编委;山东省药学会药物化学专业委员会委员。

联系方式:

山东大学药学院药物化学研究所, (济南市文化西路44号邮编250012) Tel. 086-531-88380270, Fax. 086-531-88382548E-mail: xinyongl@sdu.edu.cn

主要研究领域:

基于靶点的抗病毒药物的合理设计、合成与活性研究。本研究方向主要基于病毒(HIVHBVFluV)生命周期的分子生物学过程,针对病毒复制过程的关键酶或蛋白等靶点结构,通过计算机辅助,进行合理药物的设计、合成及抗病毒活性的研究。目前主要开展基于HIV-1逆转录酶的非核苷类抑制剂、核苷类及其大分子缀合物的前药研究;开展基于HIV-1侵入过程病毒gp120吸附抑制剂和辅助受体CCR5拮抗剂研究;开展基于HIV-1转录过程Tat-TAR相互作用、Rev-REE相互作用抑制剂的研究。同时,开展基于HBV侵入和包装过程的非核苷类抗乙肝病毒抑制剂研究;开展基于流感病毒神经氨酸酶、DNA聚合酶为靶点的抑制剂研究。

基于活性天然产物的结构修饰与心脑血管药理活性的研究。本研究方向主要开展活性天然产物的全合成、结构修饰和抗缺血、抗血栓、抗血脂、抗氧化损伤等心脑血管活性研究。目前主要开展中药川芎活性成分川芎嗪、川芎咔啉碱衍生物的结构修饰研究。

主要科研成果

近几年在JMC; Bioorg.Med. Chem. Lett; Bioorg.Med. Chem.; ChemMedChem; Curr.Med.Chem; Curr.Pharm.Des.; Mini Rev Med. Chem.; Arch. Pharm; Arch Pharm Res; Curr HIV Res; ChemBiodive.; Antiviral Res.;Heterocycles; Molecules; Chemical Biology & Drug Design; Drug Futur; Chin Chem. Letter、中国化学、有机化学、药学学报、中国药学杂志、中国药物化学杂志、中国医药工业杂志等发表文章200余篇;其中被SCI收录80余篇(论文见附录);主编《抗艾滋病药物研究》专著(人民卫生出版社,北京,200612月)、主编《有机化合物制备与分离技术》专著(人民卫生出版社,北京,20112月)、主编《无机化学》、副主编《无机化学教程》教材;参编《分子核医学》、《现代生物医学示踪技术》(王世真院士主编) 等专著6部。曾荣获山东省科技进步一等奖1项(第二,2012);山东省教育厅科技进步三等奖2项,山东省高等学校优秀科研成果奖一等奖、二等奖各1项(第一,20102005);申报国家发明专利30余项,其中已获得发明专利授权17项;曾获2001山东省青年科技奖、2004山东省优秀中青年重点科技人才、2004年济南市青年科技明星奖、2002年山东大学优秀青年知识分子、2007年山东大学十大优秀教师、20092012年度山东大学优秀研究生指导教师,2009山东大学十大新闻人物提名奖、2010 山东省医学领军人才、2011获享受国务院政府特殊津贴等荣誉称号。

在药物开发与产业化方面:曾经与企业合作,成功开发了头孢地嗪抗生素、抗心律失常药物尼非卡兰、抗菌药物奥硝唑分散片、抗病毒药物泰诺福韦酯原料及片剂、质子泵抑制剂埃索美拉唑镁、钠等仿制药物,为企业创造了较大的经济和社会效益。

承担科研项目情况

在从事抗病毒药物研究方面,曾主持科技部中国-西班牙政府间国际合作课题含硫杂环化合物的合成及其生物活性研究”(1997.1-1999.12)新型蒽醌酮类化合物的合成及其抗病毒、抗肿瘤活性研究”(2002.1-2004.12);主持科技部国际合作重点项目新型非核苷类HIV逆转录酶抑制剂的研究303DF0000332003.10-2006.1250万);主持国家自然基金噻吩并噻二嗪新型非核苷类HIV逆转录酶抑制剂的研究30371686, 2004.1-2006.12)、取代噻二嗪类HIV-1非核苷类逆转录酶抑制剂的设计、合成与活性研究308731332009.1-2011.12)、吡咯并噻三嗪类HIV-1非核苷类逆转录酶抑制剂的设计、合成与活性研究307726292008.01-2010.12)、靶向于HIV-1多靶点蛋白gp120的非等同双靶点抑制剂研究(国家自然基金-海外和港澳学者合作基金,30928031, 2010.01-2012.12 国内课题主持人);另外,主持山东省自然基金等课题。
在从事心脑血管药物研究方面,曾主持国家重大新药创制科技专项候选药物川芎嗪阿魏酸酯抗心脑血管疾病候选药物研究2009ZX09103-117,科技部,2009.1-2012.1)、山东省科技发展计划项目(2006GG2202063 2007.1-2009.12)、山东省自然基金、山东省1020计划、济南市青年科技明星计划项目等课题研究。
目前正在主持的课题:

1)新型六元芳杂环类抗耐药性HIV-1 NNRTI的设计、合成与活性研究. 国家自然基金,项目编号: 81273354, 2013.01-2016.12  课题主持人

2)新型HEPTHIV-1非核苷类逆转录酶抑制剂的设计、合成与活性研究,国家自然基金重大国际合作项目,项目编号:  30910103908;  2010.01-2013.12  课题主持人

3). 三苯双咪国际合作项目(新华制药联合项目),国家重大新药创制:山东省创新药物孵化基地建设,(2010ZX09401-302-3-1),2010.5-2013.5

4). 阿司匹林原料药技术改造(新华制药联合项目),国家重大新药创制“125”第一批项目(2011ZX09203-001-01):2011.5-2014.5

5) 新型抗耐药性HEPTHIV-1非核苷类逆转录酶抑制剂的设计、合成与活性研究. 教育部博士点基金优先发展领域课题。项目编号: 20110131130005 2011.1-2013.12, 主持人

6)取代噻二嗪类HIV-1非核苷类逆转录酶抑制剂的设计合成及活性研究。山东省自然基金,项目编号: ZR2009CM016  2009.12-2012.12  课题主持人
 
获得授权专利

1.刘新泳, 徐文方等,川芎醇酯类衍生物及其制备方法和含有川芎醇酯类衍生物的药物组合物与应用。中华人民共和国国家知识产权局,中国发明专利, ZL02135989.X , 2005-1-12

2.刘新泳,徐文方, 程先超等川芎嗪烃基哌嗪类衍生物、制备方法和药物组合物与应用。中华人民共和国国家知识产权局,中国发明专利,专利号:ZL200510045307.4,(2007-7-18

3.刘新泳,徐文方, 闫任章等. 24-二取代杂环并[4,5-e][1,2,4]噻二嗪衍生物制备方法. 中华人民共和国国家知识产权局。专利号:ZL2006 1 0043834.6  2008-6-11

4. 刘新泳,徐文方, 闫任章等.  N4-取代吡唑[4,5-e]]1,2,4]噻二嗪类衍生物、制备方法及其药物组合物与应用。中华人民共和国国家知识产权局。专利号:ZL200510044297.2  2009-5-6

5. 刘新泳,徐文方, 林永强等.  N1,N3-二取代噻吩并[3,2-e][2,1,3]噻二嗪-2,2,4-三酮类衍生物与应用。中华人民共和国国家知识产权局。专利号:ZL 200610043833.1 2009617

6. 刘新泳,李锦等.  N1N3-二取代吡唑并[4,5-e][2,1,3]噻二嗪-2,2,4-三酮类衍生物及其制备方法与应用。专利号:ZL200710015052.6  中华人民共和国国家知识产权局,2009729

7. 刘新泳, 常昱等. 聚乙二醇修饰齐夫多定缀合物及其制备方法与应用,中华人民共和国国家知识产权局,专利号: ZL200710015587.3,   授权日:2010-1-21

8.刘新泳,邓利娟等, 川芎嗪茋类衍生物、制备方法和药物组合物与应用。中华人民共和国国家知识产权局,专利号: ZL200710014906.9, 授权日:2010-2-03

9. 刘新泳,于芳等, 川芎嗪胍类衍生物的制备方法及其应用。中华人民共和国国家知识产权局。专利号: ZL200810157518.0,  授权日:2010-06

10. 刘新泳,于芳等. 川芎嗪酰胺类衍生物、制备方法和药物组合物与应用。专利号:ZL200810157251.5, 授权日:2011-3-16

11. 刘新泳, 展鹏等. 123-噻二唑巯乙酰胺类衍生物及其制备方法。专利号:ZL200910016414.2,授权日:2011-2-16

12. 刘新泳, 于明艳等. 2-[(取代苯氨基)羰基甲硫基]-6-(2,6-二氯苄基)-3H-嘧啶-4-酮类衍生物及其制备方法与应用 ZL200910017725.0,授权日:2011.4.27

13. 刘新泳, 展鹏等. N-取代苯基-2-(1-芳基-1H-咪唑-2-巯基)乙酰胺类衍生物及其制备方法与应用. 专利号:ZL200810157250.0  授权日: 2011-4-27

14.刘新泳, 展鹏, 方增军.  123-硒二唑巯乙酰胺类衍生物及其制备方法与应用。发明专利专利号:ZL200910016413.8,授权日: 2011-6-15

15. 刘新泳, 展鹏, 方增军,李震宇. 取代噻唑巯乙酰胺类衍生物及其制备方法与应用。发明专利,专利号:ZL201010223400.0,授权日: 2012-7-25

16. 刘新泳, 展鹏, 方增军。2-(2-取代芳基-2H-1,2,4-三唑-3-巯基)乙酰胺衍生物及其制备方法与应用,发明专利,专利号:ZL201010223401.5,授权日: 2012-7-25

17. 刘新泳,李震宇,展鹏。5-取代-2-4-取代苯基)苯并噁唑类衍生物及其制备方法与应用。发明专利,专利号:ZL201110021056.1, 授权日:2012-10- 3
5发表代表论文
2013

1. Wenjun Li, Peng Zhan, Erik De Clercq, Hongxiang Lou*,Xingyong Liu*. Current Drug research on PEGytion with small molecular agents.Progress in Polymer Science, 2013; 38: 421-444. (IF= 24.1)

2. Peng Zhan, Xuwang Chen, Dongyue Li, Zengjun Fang, Erik De Clercq, Xinyong Liu*. HIV-1 NNRTIs: Structural diversity, pharmacophore similarity, and implications for drug design.Medicinal Research Review, 2013; 33(S1): E1-E72  (IF=10.7)

3. Yu’ning Song, Peng Zhan,* Dongwei Kang, Xiao Li, Ye Tian, Zhenyu Li, Xuwang Chen,   Wenmin Chen, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Discovery of novel pyridaziylthioacetamides as potent HIV-1 NNRTIs usinga structure-based bioisosterism approach.Medicinal Chemistry Communications. 2013; 4(5): 810-816 

4. Zhenyu Li, Yuan Cao, Peng Zhan, Christophe Pannecouque, Erik De Clercq, Xinyong Liu*. Synthesis and anti-HIV evaluation of novel 1,2,4-triazole derivatives as potential non-nucleoside HIV-1 reverse transcriptase inhibitors. Letters in Drug Design & Discovery, 2013; 10(1): 27-34

5. Yu'ning Song, Peng Zhan, Qingzhu Zhang and Xinyong Liu*. Privileged Scaffolds or Promiscuous Binders: A Glance of Pyrrolo[2,1-f][1,2,4]triazines and Related Bridgehead Nitrogen Heterocycles in Medicinal Chemistry. Current Pharmaceutical Design. 2013; 19(8): 1528-1548

6. Peng Zhan, Xinyong Liu*. Multivalent agents: a novel concept for anti-HIV drug discovery. Current Medicinal Chemistry, 2013, 20(6): pp. 815-832

7. Dongyue Li, Peng Zhan, Huiqing Liu, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Xinyong Liu*. Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.Bioorganic & Medicinal Chemistry. 2013; 21(7): 2128-34.

8. Xuwang Chen, Shufang Ding, Peng Zhan and Xinyong Liu*. Recent Advances of Diaryl Ether Family as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. Current Pharmaceutical Design.2013; 19(15): 2829-2838

9. Hongfei Chen, Guoning Li, Peng Zhan, XiuliGuo, Qian Ding, Shouxun Wang and Xinyong Liu*. Design, synthesis and biological evaluation of novel ligustrazinylated derivatives as potent cardiovascular agents. Med. Chem. Commun., 2013, 4, 827-832

10. SUN Sang-Dun, MI Si-Qi, YOU Jing, YU Ji-Liang, HU Song-Qing, LIU Xin-Yong. HQSAR Study and Molecular Design of Benzimidazole Derivatives as Corrosion Inhibitors[J]. Acta Phys. Chim.Sin.,2013, 29 (6), 1192-1200

11. Zhenyu Li, Fang Yu, Lei Cui, Chen Wenmin, Shouxun Wang, Peng Zhan, Xinyong Liu*. Ligustrazine Derivatives. Part 8: Design, Synthesis, and Preliminary Biological Evaluation of Novel Ligustrazinyl Amides as Cardiovascular Agents. Medicinal Chemistry. Accepted

12. Hongfei Chen; Guoning Li; Qian Ding; Lei Cui; Peng Zhan; Shouxun Wang; Xinyong Liu*Ligustrazine derivatives. Part 8: Design, synthesis and biological evaluation of novel ligustrazinylated derivatives as potent cardiovascular agents. Bioorganic & Medicinal Chemistry Letter, submitted

13. Peng Zhan, Xiao Li, DiwakarRai, Erik De Clercq and Xinyong Liu*.Rationally designed multivalent anti-HIV agents.Curr Top Med Chem. Accepted

14. Zhenyu Li, Yuan Cao, Peng Zhan, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, YuemaoShen and Xinyong Liu*. Arylazolylthioacetanilide. Part 11: Design, synthesis and biological evaluation of 1,2,4-triazole thioacetanilide derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Medicinal Chemistry, 2013, 9, 000-000

15. Tian Ye, Xinyong Liu*. Design, synthesis and biological evaluation of novel 3,5-disubstituted-1,2,6-thiadiazine-1,1-dione derivatives as HIV-1 NNRTIs (CBDD-RA-02-13-1571) . Chemical Biology & Drug Design.

16. Xuwang Chen, Yuanyuan Li, Shufang Ding, Jan Balzarini, Christophe Pannecouque, Erik De Clercq and Xinyong Liu. Discovery of Piperidine-Linked Pyridine Analogues as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors.Acceptance of Your Manuscript cmdc.201300130 for ChemMedChem.
 
2012

1. Dongyue Li, Peng Zhan, Erik De Clercq, Xinyong Liu*. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of six representative candidates. Journal of Medicinal Chemistry, 2012, 55 (8), pp 3595–361. (IF= 5.2) (DOI: 10.1021/jm200990c)

2. Xuwang Chen, Peng Zhan, Xin Liu, Ziheng Cheng, CaicaiMeng, Siyuan Shao, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*, Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors. Bioorganic & Medicinal Chemistry, 2012: 20 : 3856–3864

3. Wenjiun Li, Jingde Wu, Peng Zhan, Yu Chang, Christophe Pannecouque, Erik De Clercq&Xinyong Liu*. Synthesis, drug release and anti-HIV Activity of a series of PEGylatedzidovudine conjugates. International Journal of Biological Macromolecules. 2012;50(4): 974-980

4. Xuwang Chen, Peng Zhan, Christophe Pannecouque, Jan Balzarini, Erik De Clercq and Xinyong Liu*. Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2012; 51: 60-66

5. Peng Zhan, Wenmin Chen, Zhenyu Li, Xiao Li, Xuwang Chen, Ye Tian, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Structure-based Bioisosterism Design, Synthesis and Biological Evaluation of Novel 1,2,4-Triazin-6-ylthioacetamides As Potent HIV-1 NNRTIs. Bioorganic & Medicinal Chemistry Letters. 2012; 22: 7155–7162

6. Peng Zhan, Wenmin Chen, Zhenyu Li, Xiao Li, Xuwang Chen, Ye Tian, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Discovery of Novel 2-(3-(2-Chlorophenyl) pyrazin-2-ylthio)-N-arylacetamides As Potent HIV-1 Inhibitors Using a Structure-Based Bioisosterism Approach. Bioorganic & Medicinal Chemistry, 2012, Volume 20, Issue 23,   Pages 6795–6802

7. Xiao Li, Peng Zhan*, Hong Liu, Dongyue Li, Liu Wang , Xuwang Chen, Huiqing Liu, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Xinyong Liu*. Arylazolyl(azinyl) thioacetanilides. Part 10: Design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.Bioorganic & Medicinal Chemistry.2012; 20: 5527-5536

8. Peng Zhan, Xuwang Chen, Dongyue Li, Zengjun Fang, Erik De Clercq, Xinyong Liu*Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and Biological Investigation of      Thiazolylthioacetamides Derivatives as A Novel Class of Potential Antiviral Agents. Archives of Pharmacal Research, 2012;Vol 35, No 6, 975-986,

9. Lijuan Deng, XiuliGuo, Li Zhai, Yuning Song, Hongfei Chen, Peng Zhan, Jingde Wu, Xinyong Liu*. Ligustrazine derivatives. Part 4: Design, synthesis and biological evaluation of novel Ligustrazine-based stilbene derivatives as potential cerebrocardiac vascular agents. Chemical Biology & Drug Design. 2012 May ; 79 ( 5 ): 731-739 (DOI: 10.1111/j.1747-0285.2012.01332.x)

10. Wenwen Chen, Peng Zhan, Erik De Clercq and Xinyong Liu*.Recent Progress in Small Molecule CCR5 Antagonists as Potential HIV-1 Entry Inhibitors. Current Pharmaceutical Design, 2012; 18(1): 4165-4186

11. Zhenyu Li, Peng Zhan, LieveNaesens, EvelienVanderlinden, Ailin Liu, Guanhua Du, Erik De Clercq and Xinyong Liu*. Synthesis and preliminary biological evaluation of 5-substituted-2-(4- substituted phenyl) benzoxazoles as a novel class of influenza virus A inhibitors. Chemical Biology & Drug Design. 2012; 79 ( 6 ): 1018-24

12. Ye Tian, Peng Zhan, DiwakarRai, Jiyan Zhang, Erik De Clercq and Xinyong Liu*. Recent Advances in the Research of 2,3-Diaryl-1,3-thiazolidin-4-one Derivatives as Potent HIV-1 NNRTIs. Current Medicinal Chemistry, 2012; 19(13): 2026-2037.

13. Wenmin Chen, Peng Zhan, Jingde Wu, Zhenyu Li and Xinyong Liu*.The Development of HEPT-type HIV Non-Nucleoside Reverse Transcriptase Inhibitors and Its Implications for DABO Family. Current Pharmaceutical Design, 2012, 18, 4165-4186

14. Xiaofei Jiang, Peng Zhan, Xinyong Liu*& Erik De Clercq. Synthesis and Anti-HIV Activity Evaluation of 2-(5-(Naphthalen-1-yl)-1,2,3-thiadiazol-4-ylthio)-N-acetamides Derivatives. Lat.Am. J. Pharm. 2012; 31 (5): 751-755

15. Zhenyu Li, Fang Yu, Lei Cui, Peng Zhan, Shouxun Wang* and Xinyong Liu*. Ligustrazine derivatives. Part 6: Design, synthesis and evaluation of novel ligustrazineacylguanidine derivatives as potential cerebrocardiac vascular agents. Medicinal Chemistry.2012 Jun 25. 2012;8(5):928-33.

16. Xiao Li, Peng Zhan, Erik De Clercq, Xinyong Liu*. The HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors (Part V): Capravirine and Its Analogues. Current Medicinal Chemistry, 2012; 19 ( 36): Pp.6138-6149

17. Peng Zhan, Dongyue Li, Junyi Li, Xuwang Chen and Xinyong Liu*.Benzimidazole (Benzimidazolone) Heterocycle as A Privileged Scaffold in Antiviral Agents. Mini-Review in Organic Chemistry, 2012, 9, 397-410

18. Zhai L, Zhang P, Sun RY, Liu XY, Liu WG, GuoXL.Cytoprotective effects of CSTMP, a novel stilbene derivative, against H2O2-induced oxidative stress in human endothelial cells. Pharmacol Rep. 2012, Nov;63(6):1469-80.
 
2011

1. Zhang Jing, Zhan Peng, Wu Jingde, Li Zhenyu, Jiang Yan, GeWeiying, Pannecouque C, De Clercq E, Liu Xinyong*. Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6- ((3,4-dihydroquinolin-1(2H)-yl)methyl) pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.Bioorganic & Medicinal Chemistry, 2011; 19: 4366–4376

2. Mingyan Yu, Zhenyu Li, Shuai Liu, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Synthesis and biological evaluation of 6-substituted 5-alkyl-2-(phenylaminocarbonyl -methylthio)pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. ChemMedChem2011; 6(5): 826–833

3. Mingyan Yu, Xinyong Liu*, Ailin Liu, Guanhua Du, LieveNaesens, EvelienVanderlinden, Erik De Clercq.Discovery of dihydro-alkyloxy-benzyl-oxopyrimidines as promising anti-influenza virus agents.Chemical Biology & Drug Design, 2011, 78(4): 596–602

4. Peng Zhan, Xuwang Chen, Dongyue Li, Wenwen Chen, Ye Tian, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*.Arylazolylthioacetanilide part 8.  Design, Synthesis and Biological Evaluation of Novel 2-(2-(2,4-Dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N- arylacetamides As Potent HIV-1 Inhibitors. European Journal of Medicinal Chemistry. 2011; 46 : 5039-5045

5. Zhan Peng, Li Dongyue, Chen Xuwang, Liu Xinyong*, De Clercq Erik.Functional Roles of Azoles Motif in Anti-HIV Agents.Current Medicinal Chemistry, 2011; 18(1): 29-46

6. Hongfei Chen, Peng Zhan,Xinyong Liu*.Ligustrazine derivatives. Part 5: Design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents. European Journal of Medicinal Chemistry. 2011;46: 5609-5615

7. Zhan Peng, Liu Xinyong*. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010). Expert Opin.Ther. Patents (2011) ; 21(5):1-80

8. Jiang Yan, Liu Xinyong*, De Clercq Erik. New Therapeutic Approaches Targeted at the Late Stages of the HIV-1 Replication Cycle. Current Medicinal Chemistry,2011; 18(1): 16-28

9. Mingyan Yu, Erkang Fan, Jingde Wu and Xinyong Liu*. Recent Advances in the DABOs Family as Potent HIV-1 non-Nucleoside Reverse Transcriptase Inhibitors. Current Medicinal Chemistry,2011, 18(16): 2376-2385

10. Zhang Jing, GeWeiying, Zhan Peng, De Clercq E, Liu Xinyong*. Retroviral Restriction Factors TRIM5α: Therapeutic Strategy to Inhibit HIV-1 Replication. Curr Med Chem. 2011; 18(17): 2649-2654.

11. Xuwang Chen, Peng Zhan, Dongyue Li, Erik De Clercq and Xinyong Liu*.Recent Advances in DAPYs and Related Analogues as HIV-1 NNRTIs. Current Medicinal Chemistry, 2011, 18, 359-376

12. Zhenyu. Li, Peng. Zhan andXinyong Liu*. 1,3,4-Oxadiazole: A Privileged Structure in Antiviral Agents. Mini-Reviews in Medicinal Chemistry, 2011, 11: 1130-1142

13. Peng Zhan, Xuwang Chen, Xinyong Liu*, Christophe Pannecouque, LieveNaesens, Erik De Clercq, Ailin Liu, Guanhua Du. Thiazolylthioacetamides as a Novel Class of Potential Antiviral Agents. Antiviral Research, Volume 90, Issue 2, May 2011, Page A67.

14. Wenjun Li, Peng Zhan, Jingde Wu, Yu Chang, Christophe Pannecouque, Erik De Clercq, Xinyong Liu.* Synthesis, Influence of Polymer Molecular Weight on Drug Release and Anti-HIV Activity of PEGylated AZT Conjugates.Antiviral Research,Volume 90, Issue 2, May 2011, Page A37.

15. Peng Zhan, Renzhang Yan, Xinyong Liu,*, Christophe Pannecouque, MyriamWitvrouw , Erik De Clercq, Maria Teresa Molina, Salvador Vega. Synthesis and anti-HIV activity of novel 2,4-disubstituted-7-methyl- 1,1,3-trioxo-2H,4H-pyrazolo[4,5-e] [1,2,4]thiadiazine derivatives. Drug Discoveries & Therapeutics. 2011; 5(6):279-285.

16. Hu Song-Qing, Mi Si-Qi, Jia Xiao-Lin, Fan Cheng-Cheng, Chen Sheng-Hui, Zhang Jun, Liu Xin-Yong*. 3D-QSAR Study and Molecular Design of Benzimidazole Derivatives as Corrosion Inhibitors.Chemical Journal Of Chinese Universities. 2011, Vol. 32 Issue (10) :2402-2409

17. Yu-Ning Song, Xiu-Li Guo, Bei-BeiZheng, Xin-Yong Liu, Xue Dong, Lu-Gang Yu, Yan-Na Cheng. Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTπ activity. Toxicol.Vitro.2011; vol. 25, no. 4, pp. 937-943,

版权所有:山东大学大学技术转移中心 联系地址:济南市山大南路27号山东大学明德楼C座411 邮编:250100 电话:0531-88364752
CopyRight © 2014-2016 All Rights Reserved By The Technology Transfer Center of Shandong University